Training activity information
Details
Analyse, interpret and draft a clinical report for testing in the diagnosis of other lymphomas to include:
- Lymphoplasmacytic lymphoma
- Low grade lymphomas
Type
Entrustable training activity (ETA)
Evidence requirements
Evidence the activity has been undertaken by the trainee repeatedly, consistently, and effectively over time, in a range of situations. This may include occasions where the trainee has not successfully achieved the outcome of the activity themselves. For example, because it was not appropriate to undertake the task in the circumstances or the trainees recognised their own limitations and sought help or advice to ensure the activity reached an appropriate conclusion.
Reflection at multiple timepoints on the trainee learning journey for this activity.
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
What does success look like?
- Identify what is expected of you in relation to analysing, interpreting, and drafting a clinical report for the diagnosis of lymphoplasmacytic and low-grade lymphomas.
- Consider how the learning outcomes apply, specifically in relation to report preparation and interpreting relevant findings, particularly clonality status.
- Discuss with your training officer to gain clarity of what is expected of you in relation to expectations for using objective language to describe clonality and differentiation from reactive processes.
What is your prior experience of this activity?
- Think about your knowledge of genetic features and relevant assays (e.g., clonality assessment) for lymphoplasmacytic and low-grade lymphomas.
- Consider possible challenges you might face during the activity, such as difficulty distinguishing between a reactive process and a low-level neoplastic clone, selecting the most appropriate material for testing and reconciling potential discrepant results due to different levels of tumour infliteration (e.g., peripheral blood vs bone marrow aspirate or trephine vs lymph node) or interpreting ambiguous clonality assessment results.
- Recognise the scope of your own practice for this activity i.e. know when you will need to seek advice or help, and from whom. You will need to seek advice from your Training Officer when required, for example if the clonality assessment is equivocal or if findings conflict with the initial pathology suggesting a reactive process.
- Acknowledge how you feel about contributing to the definitive diagnosis of a chronic lymphoma.
What do you anticipate you will learn from the experience?
- Consider the specific skills you want to develop, such as mastering the analysis and interpretation of clonality assays and relevant gene mutation testing.
- Identify the specific insights you hope to gain into how genomic findings contribute to the classification and diagnosis of indolent (low-grade) lymphomas.
What additional considerations do you need to make?
- Consult actions identified following previous experiences of analysing molecular assays for diagnosis.
- Identify important information you need to consider before embarking on the activity, such as the relevant clinical and morphological data which provides essential context for interpreting the molecular findings.
In action
Is anything unexpected occurring?
- Are you noticing anything surprising or different from what you anticipate whilst analysing the data and interpreting the results for low grade lymphomas?
- Are you encountering situations such as:
- Ambiguous molecular data for clonality that challenges the distinction between neoplastic and reactive processes?
- Conflicting results from different tissue types e.g. bonemarrow aspirate vs trephine or vs lymph node?
- Difficulty integrating findings from multiple assays (e.g., molecular and immunophenotypic data)?
- Unusual findings that do not clearly fit standard classification criteria for lymphoplasmacytic lymphoma?
How are you reacting to the unexpected development?
- How is this impacting your actions? For example, are you responding to the situation appropriately? Are you adapting or changing your approach to analysis by immediately consulting specific criteria for low-grade lymphoma classification?
- Consider the steps you are taking in the moment, such as immediately re-running a basic analysis to verify a subtle abnormality or seeking additional resources to interpret complex molecular findings.
- How are you feeling in that moment? For instance, are you finding it difficult to distinguish subtle clonal populations? Is it affecting your confidence in accurately classifying the lymphoma subtype?
What is the conclusion or outcome?
- Identify how you are working within your scope of practice. For example, are you successfully integrating results from multiple assays to arrive at a diagnosis? Or are you needing support because the complexity of the findings requires expert opinion from a pathologist or senior scientist?
- What are you learning as a result of the unexpected development? For example, are you gaining insight into the characteristic features and diagnostic criteria that differentiate between indolent lymphoma subtypes?
On action
What happened?
- Begin by summarising the key steps you took when analysing the data and drafting the clinical report for the diagnosis of the lymphoplasmacytic lymphoma or low-grade lymphoma case(s).
- Consider specific events, actions, or interactions which felt important, such as identifying the data points critical for confirming the diagnosis of these subtypes (e.g., clonality assessment or specific gene mutation status).
- Include any ‘reflect-in-action’ moments where you had to adapt to the situation as it unfolded, for instance, immediately consulting international classification criteria when faced with subtle or ambiguous clonality results.
- How did you feel during this experience, e.g., did you feel focused on meticulous classification or challenged by the necessity of differentiating a reactive process from an early low-grade malignancy?
How has this experience contributed to your developing practice?
- Identify what learning you can take from this experience regarding classification and reporting of indolent lymphomas. What strengths did you demonstrate, e.g., improved understanding of the testing and reporting requirements for these subtypes?
- What skills and/or knowledge gaps were evident, e.g., difficulty differentiating the molecular features of two closely related low-grade subtypes using international guidelines?
- Compare this experience against previous engagement with similar activities – were any previously identified actions for development achieved? Has your practice improved in your ability to classify heterogeneous lymphoid malignancies and prepare interpretive reports for common haematological malignancies?
- Identify any challenges you experienced, such as needing to seek advice or clarification on scope of practice regarding the required language in the report conclusion for an indolent vs. a more aggressive subtype based on molecular findings, and how you reacted to this.
What will you take from the experience moving forward?
- Identify the actions or ‘next steps’ you will now take to support the assimilation of what you have learnt, including from any feedback you have received, with regards to specific aspects of classification criteria or molecular findings for these lymphomas.
- What will you do differently next time you approach interpretation, for instance, by proactively reviewing the molecular, cytogenetic, or immunophenotypic data relevant to these diagnoses before finalising the interpretation?
- Do you need to practise any aspect of the activity further, such as reviewing case studies illustrating ambiguous clonality results or key knowledge outcomes related to classifying disorders using international guidelines?
Beyond action
Have you revisited the experiences?
- How have your subsequent experiences of analysing and reporting low-grade lymphomas and lymphoplasmacytic lymphoma since completing this specific training activity led you to revisit your initial approach or decisions during that activity? For example, how an instance where a subsequent lymphoplasmacytic lymphoma case required meticulous clonality assessment to differentiate from a reactive process forced you to re-evaluate the diligence of your analytical comparison protocol you applied during your first attempt at this training activity?
- Considering what you understand about clonality, classification criteria, and reporting indolent malignancies now, were the actions or considerations you identified after your initial reflection on this training activity sufficient? How have you since implemented or adapted improvements in your interpretive methodology and reporting accuracy for subtle molecular findings based on further learning and experiences? For example, how you proactively reviewed and integrated standardised reporting language to classify equivocal clonality findings?
- Has discussing cases where ambiguity in clonality led to diagnostic delays or the impact of imprecise reporting on surveillance protocols with colleagues, peers, or supervisors changed how you now view your initial experience in this training activity? For example, how professional storytelling with a senior pathologist about a report where a low-level clone was initially misclassified as reactive refined your understanding of the critical nature of accurate clonality assessment in low-grade lymphomas?
How have these experiences impacted upon current practice?
- How has the learning from this initial training activity, in combination with subsequent experiences, contributed to your overall confidence and competence in analysing and reporting molecular findings for indolent lymphomas, particularly in preparing for assessments? For example, how your accumulated ability in differentiating subtle clonal populations from background noise now enables you to confidently discuss the diagnostic criteria during a relevant assessment?
- How has reflecting back on this specific training activity, combined with everything you’ve learned since, shaped your current approach to reporting low-grade lymphomas? How does this evolved understanding help you identify when something is beyond your scope of practice or requires escalation? For example, how your evolved approach means you now routinely seek advice immediately when findings suggest transformation of an indolent lymphoma to a more aggressive subtype?
- Looking holistically at your training journey, how has this initial reporting experience, revisited with your current perspective, contributed to your development in applying comprehensive diagnostic criteria and ensuring reports support appropriate patient surveillance?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 4 |
Outcome
Analyse, interpret and prepare interpretive reports for common haematological malignancies, including results for somatic variants, clonality, and somatic hypermutation. |
| # 5 |
Outcome
Interpret the associated IQC and EQA of the laboratory tests for investigation of haematological malignancies. |
| # 6 |
Outcome
Practice with the relevant specialties for the diagnosis, monitoring and management of haematological malignancies. |